Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease

The Annals of Pharmacotherapy
Catherine J ConeGlen H Murata

Abstract

To report a case of idiosyncratic hepatotoxicity associated with metformin in the treatment of type 2 diabetes with nonalcoholic fatty liver disease (NAFLD). A 61-year-old obese man presented with jaundice, nausea, fatigue, and an unintentional weight loss 2 weeks following initiation of metformin. Laboratory findings revealed aminotransferase values 10-15 times the upper limit of normal. Potential causative agents, including metformin, simvastatin, and Niaspan (extended-release niacin), were discontinued. Two months later, the patient's signs and symptoms had resolved and aminotransferase values returned to normal. An objective causality assessment revealed that the adverse reaction was probably associated with metformin. Since numerous medications and disease states can cause abnormalities in liver enzymes, it is important for providers to be able to distinguish the cause(s) and take appropriate actions. This can take a great deal of time and effort in patients with multiple medications and comorbidities. In this patient's case, viral hepatitis, worsening NAFLD, and the concomitant drugs were highly suspected. As hydroxymethylglutaryl coenzyme A reductase inhibitors offer substantial cardiovascular benefits and as metformin i...Continue Reading

References

Jun 17, 1998·The American Journal of Medicine·M M BabichM L Shiffman
Jan 23, 1999·The American Journal of Cardiology·D M CapuzziJ Brody
Jan 23, 1999·The American Journal of Cardiology·J R Guyton, D M Capuzzi
May 11, 1999·The American Journal of Gastroenterology·M HartlebK Januszewski
Jul 27, 2001·The American Journal of Gastroenterology·D J DesiletsK C Holtzmuller
Oct 27, 2001·The American Journal of the Medical Sciences·A SchattnerJ Friedman
Jun 14, 2002·The American Journal of Cardiology·Keith G Tolman
Oct 31, 2002·Gastroenterology·Arun J Sanyal, UNKNOWN American Gastroenterological Association
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Oct 17, 2003·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Fadel E NammourSteven R Peikin
Dec 18, 2003·Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie·Murat KiyiciFaruk Memik
Mar 5, 2004·Annals of Internal Medicine·M DeutschS P Dourakis
May 12, 2004·Atherosclerosis·Loukianos S RallidisAikaterini S Parasi
Jul 28, 2004·The American Journal of Cardiology·Melvyn Rubenfire, UNKNOWN Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group
Sep 11, 2004·Journal of the American College of Cardiology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program
Dec 18, 2004·Seminars in Liver Disease·Peter Ghali, Keith D Lindor
Sep 20, 2005·Atherosclerosis·Stavros AntonopoulosGregory Giannoulis
Feb 1, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Geoffrey C Farrell, Claire Z Larter
Feb 17, 2006·The New England Journal of Medicine·Victor J Navarro, John R Senior
Mar 1, 2006·The American Journal of Geriatric Pharmacotherapy·Eiji Kutoh
Jan 19, 2007·World Journal of Gastroenterology : WJG·Raúl-J AndradeM-Isabel Lucena
Jun 26, 2007·Current Medical Research and Opinion·R S BirjmohunG Assmann
Mar 22, 2008·AJR. American Journal of Roentgenology·Chandana G LallKumaresan Sandrasegaran
Jun 20, 2008·Diabetes, Obesity & Metabolism·Mohamed H Ahmed, Christopher D Byrne
Nov 18, 2008·Metabolism: Clinical and Experimental·Hideyuki HyogoKazuaki Chayama
Jul 25, 2009·Current Treatment Options in Cardiovascular Medicine·Sweta Tandra, Raj Vuppalanchi

❮ Previous
Next ❯

Citations

Apr 23, 2011·Expert Opinion on Drug Metabolism & Toxicology·Jonathan G Stine, James H Lewis
Mar 8, 2016·Chemico-biological Interactions·Anabel García-HerediaJordi Camps
May 4, 2013·Alimentary Pharmacology & Therapeutics·J H Lewis, J G Stine
Apr 29, 2014·Archives of Toxicology·Vladislav VolarevicMiodrag L Lukic
Feb 23, 2012·Diabetes Care·Francisco Miralles-LinaresRicardo Gomez-Huelgas
Aug 22, 2018·Journal of Intensive Care Medicine·George Sam Wang, Christopher Hoyte
Dec 20, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Thamir M AlshammariKerry L LaPlante
Aug 27, 2013·The Cochrane Database of Systematic Reviews·Zhao Lan LiuJian Ping Liu
Dec 17, 2019·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Manpreet S MundiRyan T Hurt
Mar 29, 2011·Expert Review of Cardiovascular Therapy·John Richard, Ildiko Lingvay
May 20, 2020·Frontiers in Endocrinology·Ziquan Lv, Yajie Guo
Jun 1, 2021·Chemico-biological Interactions·Fatemeh Alaei FaradonbehStanislav Micuda
Jul 3, 2021·International Journal of Molecular Sciences·Isabella PanfoliDavide Maggi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology
C D Jackson, L Fishbein
The New England Journal of Medicine
R E Pieroni, L Levine
Alimentary Pharmacology & Therapeutics
M García-CortésSpanish Group for the Study of Drug-induced Liver Disease (grupo de Estudio para las Hepatopatías Asociadas a Medicamentos,
© 2021 Meta ULC. All rights reserved